Article Details
Retrieved on: 2025-05-27 14:06:21
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Pfizer's $1.25 billion licensing deal with Chinese biopharma 3SBio, highlighting the development of SSGJ-707, a bispecific antibody targeting cancer, reflecting biopharma's role in oncology and global collaborations.
Article found on: www.bioxconomy.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here